Start-up Biotech dedicated to improving lives by delivering new medicines that stop #inflammation by inhibiting #NLRP3 inflammasome
Location: Ireland, Dublin City, Dublin
Employees: 11-50
Total raised: $126.82M
Founded date: 2016
Investors 3
| Date | Name | Website |
| 22.03.2022 | Forbion | forbion.co... |
| - | Longitude ... | longitudec... |
| - | Fountain H... | fh-partner... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 25.03.2019 | - | $1M | - |
| 04.12.2018 | - | $63M | - |
| 19.11.2018 | Series B | $45.82M | - |
| 13.09.2016 | Series A | $17M | Fountain H... |
Mentions in press and media 15
| Date | Title | Description |
| 12.06.2026 | Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 12, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody ther... |
| 23.09.2020 | Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies | - Longitude Venture Partners IV will build on the Firm’s commitment to improve clinical outcomes, enhance patient quality of life, and drive efficiency in healthcare delivery - - In 2020 to date, Longitude portfolio companies announced 4 IP... |
| 23.09.2020 | Healthcare VC Firm Longitude Capital Closes $585M Fund | What You Should Know: – Healthcare venture capital firm Longitude Capital announces the close of its $585M Longitude Venture Partners IV, L.P. (“LVP4”) fund to invest in transformative healthcare companies. – LVP4 will invest opportunistica... |
| 25.03.2019 | Inflazome Raises Over US$1M in Funding | Inflazome, a Dublin, Ireland- and Cambridge, UK-based biotech company developing several small molecule drugs that inhibit harmful inflammation, received an over US$1m grant. The Michael J. Fox Foundation for Parkinson’s Research (MJFF) pro... |
| 25.03.2019 | J&J, Bayer agree to $775M payout to settle Xarelto litigation; Biogen launches $5B buyback in the wake of a disaster; Hookipa pitches $86M IPO | → Right on deadline this morning we learned that J&J and Bayer have reached a deal to settle their outstanding litigation on Xarelto with a lump $775 million settlement. The two companies were accused of failing to warn... |
| 25.03.2019 | Inflazome receives funding from The Michael J. Fox Foundation for Parkinson’s research | Inflazome, the pioneering biotech company developing several small molecule drugs that inhibit harmful inflammation, today announces it has been awarded funding in excess of US$1 million by The Michael J Fox Foundation for Parkinson’s Resea... |
| 25.03.2019 | Inflazome receives funding from The Michael J. Fox Foundation for Parkinson’s research | Inflazome receives funding from The Michael J. Fox Foundation for Parkinson’s research 25-03-2019 Inflazome, the pioneering biotech company developing several small molecule drugs that inhibit harmful inflammation, today announces it has be... |
| 04.12.2018 | Queensland biotech startup Inflazome raises $63 million to change the way we treat Alzheimer’s | Inflazome chief executive Matt Cooper. Source: Supplied. Biotech startup Inflazome has raised $63 million in funding to test and commercialise its molecules for slowing the progress of inflammatory diseases such as Alzheimer’s and Parkinson... |
| 19.11.2018 | Inflazome raises €40M to get NLRP3 drug into humans | Inflazome has raised €40 million ($46 million). The Forbion-led series B tees up Inflazome to trial its NLRP3 inflammasome inhibitors in several inflammatory diseases. Irish-British biotech Inflazome is working on a pipeline of small molecu... |
| 19.11.2018 | Inflazome raises €40M to get NLRP3 drug into humans | Inflazome has raised €40 million ($46 million). The Forbion-led series B tees up Inflazome to trial its NLRP3 inflammasome inhibitors in several inflammatory diseases. Sponsored by Agilent Technologies How would you like to win free bench s... |
Show more